Dalbavancin for treatment of implant-related methicillin-resistant Staphylococcus aureus osteomyelitis in an experimental rat model

Manuel Kussmann, Markus Obermueller, Florian Berndl, Veronika Reischer, Luzia Veletzky, Heinz Burgmann & Wolfgang Poeppl

Dalbavancin is a new semisynthetic lipoglycopeptide with improved antimicrobial activity against various gram-positive pathogens. It demonstrates an extensive plasma half-life which permits outpatient parenteral antimicrobial therapy with weekly intervals and might therefore be an excellent treatment alternative for patients requiring prolonged antimicrobial therapy. The present study investigated dalbavancin monotherapy in an experimental implant-related methicillin-resistant Staphylococcus aureus (MRSA) osteomyelitis model. A clinical MRSA isolate and a Kirschner-wire were inserted into the proximal tibia of anaesthetized Sprague-Dawley rats. Four weeks after infection 34 animals were treated over 4 weeks with either dalbavancin (20 mg/kg loading-dose; 10 mg/kg daily), vancomycin (50 mg/kg twice daily) or left untreated. Twenty-four hours after the last treatment dose tibial bones and Kirschner-wires were harvested for microbiological examination. Based on quantitative bacterial cultures of osseous tissue, dalbavancin was as effective as vancomycin and both were superior to no treatment. No emergence of an induced glycopeptide-/lipoglycopeptide-resistance was observed after a treatment period of four weeks with either dalbavancin or vancomycin. In conclusion, monotherapy with dalbavancin was shown to be as effective as vancomycin for treatment of experimental implant-related MRSA osteomyelitis in rats, but both antimicrobials demonstrated only limited efficacy. Further studies are warranted to evaluate the clinical efficacy of dalbavancin for the treatment of periprosthetic S. aureus infections.

The increasing prevalence of drug-resistant gram-positive cocci, such as methicillin-resistant Staphylococcus aureus (MRSA) has complicated the management of difficult to treat infections. Dalbavancin, a new semisynthetic lipoglycopeptide, is currently approved for single-dose treatment of acute bacterial skin and soft tissue infections in adults. Dalbavancin possesses unique pharmacokinetic properties with an extensive plasma protein binding and a prolonged half-life (t1/2) of 181–216 hours. The in vitro activity of dalbavancin against various gram positive pathogens including MRSA and vancomycin-intermediate S. aureus (VISA) isolates was shown to be even improved when compared to established antibiotics such as linezolid, teicoplanin or vancomycin.

For implant-related MRSA-infections, in particular in osseous tissue, current treatment strategies recommend a combination of a biofilm active substance like rifampicin or fosfomycin together with vancomycin. In a recent study it was shown that dalbavancin was equally active in an MRSA-osteomyelitis model compared to vancomycin. However, hitherto no data on the efficacy of dalbavancin in the treatment of implant-related osteomyelitis is available. Thus, the present study set out to investigate the efficacy of dalbavancin compared to vancomycin in an experimental implant-related MRSA osteomyelitis rat-model.

1Department of Internal Medicine I, Division of Infectious Diseases and Tropical Medicine, Medical University Vienna, Vienna, Austria. 2Military Medical Cluster East, Austrian Armed Forces, Vienna, Austria. Correspondence and requests for materials should be addressed to H.B. (email: heinz.burgmann@meduniwien.ac.at)
Results
During induction of the experimental implant-related MRSA osteomyelitis, two out of 36 rats died during anesthesia and were not further analyzed. Thus, 12 animals remained in the dalbavancin group and 11 animals in the vancomycin and control group, respectively.

All bacterial cultures from bone and Kirschner-wires were found positive for MRSA. The mean (±SD) bacterial counts in osseous tissue were $5.96 \log_{10} \text{CFU/g bone (±0.32 \log_{10} \text{CFU/g bone)}}$ for vancomycin, $5.79 \log_{10} \text{CFU/g bone (±0.33 \log_{10} \text{CFU/g bone)}}$ for dalbavancin and $6.33 \log_{10} \text{CFU/g bone (±0.28 \log_{10} \text{CFU/g bone)}}$ for untreated animals (Fig. 1). Significant differences were shown for dalbavancin ($p < 0.01$) and vancomycin ($p = 0.03$) when compared to no treatment but not between the two antimicrobial therapies. The mean (±SD) body weight increase was $36.8 \text{g (±8.6 g)}$ in the dalbavancin group, $4.3 \text{ g (±9.4 g)}$ in the vancomycin group and $47.4 \text{g (±33.4 g)}$ in the untreated group. Thus, the body weight increase in the dalbavancin ($p < 0.001$) and the untreated control group ($p < 0.001$) were significantly higher when compared to the vancomycin group. All isolates obtained from antibiotic treated bone samples and Kirschner-wires demonstrated MICs of $0.064 \text{mg/L}$ for dalbavancin and $1.5–2 \text{mg/L}$ for vancomycin. Thus, no emergence of induced glycopeptide/lipoglycopeptide resistance occurred in the present study.

Discussion
The similar efficacy of dalbavancin and vancomycin observed in the present study is in line with a previous study by Barnea et al.10. Using an experimental sternal MRSA osteomyelitis rat model, they demonstrated a decrease of $>3 \log_{10} \text{CFU/g bone}$ after a treatment period of two weeks with either dalbavancin or vancomycin compared to untreated animals10. Thus, in terms of bacterial loads in osseous tissues, the efficacy of the antimicrobial treatment was more distinct in that osteomyelitis model without foreign body10. Several factors might contribute to this discrepancy. The MICs of the bacteria used, however, were identically for dalbavancin (0.06 mg/L) and differed only minimally for vancomycin (1.5 mg/L vs 1.0 mg/L)10. Also, with exception of the treatment period of two versus four weeks, the dosing regimens for dalbavancin and vancomycin were identically10.

Several in vitro and in vivo studies demonstrated that the antibiotic concentrations needed for biofilm eradication were approximately 10 to 1000 times higher than the MICs or even minimal bactericidal concentrations (MBCs) of planktonic cells3,11–13. Especially in low penetration compartments such as osseous tissue, these concentrations are often impossible to reach which results only in biofilm suppression but not in eradication3,13. Thus, formation of mature biofilm on the implanted Kirschner-wires might be the most suitable explanation for the low efficacy of dalbavancin and vancomycin monotherapy observed in the present study. With regard to previously performed experiments, median bacterial counts of implanted wires were only $2.5 \times 10^7 \text{CFU/implant (4.0 \times 10^2}$ to $4.5 \times 10^4$) and $7.50 \times 10^2 \text{CFU/implant (0 to 7.00 \times 10^3)}$ in the untreated control groups14,15. Therefore, it is unlikely that only a contamination through the implanted wires was responsible for the high bacterial counts obtained from the osseous tissue in the present study.

In humans, 500 mg to 1000 mg dalbavancin once weekly are usually applied to patients requiring prolonged antimicrobial therapy. Among non-infected orthopedic patients receiving a single dose of 1000 mg dalbavancin, the bone concentrations obtained were $6.3 \mu g/g (±3.1 \mu g/g)$ after 12 hours, $3.8 \mu g/g (±2.7 \mu g/g)$ after 7 days and $4.1 \mu g/g (±1.6 \mu g/g)$ after 14 days16. These concentrations indicate sufficient drug levels in osseous tissue for treatment of dalbavancin susceptible organisms16. The rationale for the treatment regimens used in the present study

Figure 1. Mean bacterial counts in $\log_{10} \text{CFU/g bone (±SD)}$ from osseous tissue after a four-week treatment period with dalbavancin, vancomycin or without treatment in an experimental implant-related MRSA osteomyelitis in rats. The three groups, dalbavancin, vancomycin and untreated, comprised twelve, eleven and eleven rats, respectively.
was to achieve bone levels of drug closely mimicking those obtained in humans. In rats, for dalbavancin a loading dose of 20 mg/kg followed by 10 mg/kg o.d. were shown to result in comparable bone levels to a single i.v. dose of 1000 mg dalbavancin in humans. However, it should be emphasized that bone concentrations of dalbavancin were assumed to have reached similar levels to those observed by Barnea et al. and were not determined in the present study.

Of interest, no emergence of dalbavancin resistant S. aureus isolates was observed after a treatment period of four weeks. This supports previous observations that development of dalbavancin resistance is rare. According to current recommendations, first-line treatment of orthopaedic implant-associated infections caused by MRSA still includes glycopeptide antibiotics such as vancomycin or teicoplanin. Thus, in regard to the similar activity to vancomycin, observed in the present study, and the unique pharmacokinetic properties, excellent for an outpatient parenteral antimicrobial therapy, dalbavancin might be a feasible alternative for long-term antimicrobial therapy of implant-related osteomyelitis.

**Conclusion**

In summary, monotherapy with dalbavancin was as effective as vancomycin for treatment of experimental implant-related MRSA osteomyelitis in rats but both antimicrobials demonstrated only limited efficacy. Further studies are warranted to investigate the clinical efficacy of dalbavancin for treatment of periprosthetic S. aureus infections, preferably in combination with biofilm active drugs.

**Methods**

**Animals.** Male Sprague-Dawley rats were housed in a temperature and light controlled facility in the level 2 biohazard area of the Institute of Biomedical Research, Medical University of Vienna, Austria. All procedures were conducted according to guidelines for animal care and use of laboratory animals and the study protocol, including care and handling of the animals, was approved by institutional Animal Welfare Committee (Medical University of Vienna, Austria).

**Pathogen.** The bacterial strain used was a clinical MRSA isolate (40496/08) obtained by routine microbiological examination from a patient with chronic osteomyelitis. Minimal inhibitory concentrations (MICs) for vancomycin (1.500 mg/L) and dalbavancin (0.064 mg/L) were determined by agar disk diffusion method with Etests (Liofilchem SRL, Italy) on Mueller Hinton agar (MHA) plates and were assessed after an incubation of 18–24 hours at 36 °C (±1°C). For dalbavancin, additionally, a recently published broth microdilution (BMD) assay, in accordance to CLSI and EUCAST convenients, was used for validation of the obtained MICs (0.063 mg/L).

**Experimental animal model.** Implant-related MRSA osteomyelitis was established in 36 Sprague-Dawley rats (Charles River WIGA GmbH, Sulzfeld, Germany) weighing 448 ± 29 g as described previously. Briefly, bacteria were grown overnight in trypticase soy broth (TSB), diluted 1:100 in fresh TSB and incubated for five hours at 36 °C (±1°C) to achieve exponential growth phase. An inoculum of 10 µl (1–5 × 10^6 CFU/bone) of the bacterial suspension and a Kirschner-wire of 1 cm length were inserted into the left proximal tibia of each animal. Bacterial counts were validated before and after surgical procedures using viable counts.

Four weeks after induction of infection animals with radiographically confirmed osteomyelitis of the tibia were randomly assigned to receive either i.p. dalbavancin (Xydalba; Angelini Pharma, Vienna, Austria) 20 mg/kg loading dose followed by 10 mg/kg daily, i.p. vancomycin (Vancomycin Hikma; Hikma Farmaceutica, Terrugem, Portugal) 50 mg/kg twice daily, or no treatment over a period of 4 weeks.

According to manufacturer’s instructions, dalbavancin and vancomycin were reconstituted using aqua ad inyectabilia and further diluted with 5% dextrose solution or aqua ad inyectabilia, respectively.

The dosage regimen was based on drug concentrations in osseous tissue obtained in previous studies in rats closely mimicking bone concentrations in humans.

**Bacterial cultures.** Twenty-four hours after the last treatment dose, rats were euthanized and tibial bones were harvested and homogenized using a liquid-nitrogen-cooled CryoMill (6770 Freezer Mill; Spex SamplePrep, Metuchen, NJ). Quantitative cultures on Columbia sheep blood (COS) agar plates were performed for bone suspensions. Before homogenizing of the tibial bones, Kirschner-wires were removed, sonicated in sterile saline for qualitative cultures and rolled on COS agar plates. Recovered bacteria of all antibiotic treated animals (n = 23) were tested for the emergence of antimicrobial resistance by agar disk diffusion method using vancomycin and dalbavancin Etests.

**Statistical analysis.** Results were analyzed using GraphPad Prism version 6. For comparison of the three treatment groups in regard to the mean bacterial counts obtained from osseous tissue and the body weight increase during the study period, the Kruskal-Wallis test with a post hoc analysis by Dunn’s multiple comparison test was used.

**Ethical approval.** The study protocol, including care and handling of the animals, was approved by institutional Animal Welfare Committee of the Medical University of Vienna, Austria (ID 66. 009/0242-MF/V/3b/2016).

**References**

1. Vaidya, P., Pawar, G. & Krishnamurthy, N. Community acquired MRSA infections—Three recent cases and an overview of CA MRSA infections. Pediatr. Infect. Dis. J., 8, 4–12 (2015).
2. Kapadia, B. H. et al. Periprosthetic joint infection. Lancet 387, 386–394 (2016).
3. Montanaro, L. et al. Emerging pathogenetic mechanisms of the implant-related osteomyelitis by Staphylococcus aureus. Int. J. Artif. Organs. 34, 781–788 (2011).
4. Leighton, A. et al. Tolerability, Pharmacokinetics, and Serum Bactericidal Activity of Intravenous Dalbavancin in Healthy Volunteers. *Antimicrob. Agents Chemother.* **48**, 940–5 (2004).
5. Cavaleri, M. *et al.* Pharmacokinetics and excretion of dalbavancin in the rat. *J. Antimicrob. Chemother.* **55**, iii31–35 (2005).
6. Buckwalter, M. & Dowell, J. A. Population pharmacokinetic analysis of dalbavancin, a novel lipoglycopeptide. *J. Clin. Pharmacol.* **45**, 1279–1287 (2005).
7. Chen, A. Y., Zervos, M. J. & Vazquez, J. A. Dalbavancin: a novel antimicrobial. *Int. J. Clin. Pract.* **61**, 853–863 (2007).
8. Moriarty, T. E. *et al.* Orthopaedic device-related infection: current and future interventions for improved prevention and treatment. *EFORT Open Rev.* **1**, 89–99 (2016).
9. Zimmerli, W. Clinical presentation and treatment of orthopaedic implant-associated infection. *J. Intern. Med.* **276**, 111–119 (2014).
10. Barnea, Y. *et al.* Efficacy of dalbavancin in the treatment of MRSA rat sternal osteomyelitis with mediastinitis. *J. Antimicrob. Chemother.* **71**, 460–463 (2016).
11. Reffuveille, F., Josse, J., Vallé, Q., Gangloff, C. M. & Gangloff, S. C. Staphylococcus aureus Biofilms and their Impact on the Medical Field, [http://www.intechopen.com/books/the-rise-of-virulence-and-antibiotic-resistance-in-staphylococcus-aureus/staphylococcus-aureus-biofilms-and-their-impact-on-the-medical-field](http://www.intechopen.com/books/the-rise-of-virulence-and-antibiotic-resistance-in-staphylococcus-aureus/staphylococcus-aureus-biofilms-and-their-impact-on-the-medical-field) (2017).
12. Fernández, J., Greenwood-Quaintance, K. E. & Patel, R. In vitro activity of dalbavancin against biofilms of staphylococci isolated from prosthetic joint infections. *Diagn. Microbiol. Infect. Dis.* **85**, 449–451 (2016).
13. Wu, H., Moser, C., Wang, H. Z., Høiby, N. & Song, Z. J. Strategies for combating bacterial biofilm infections. *Int. J. Oral Sci.* **7**, 1–7 (2015).
14. Poepl, W. *et al.* Efficacy of fosfomycin compared to vancomycin in treatment of implant-associated chronic methicillin-resistant Staphylococcus aureus osteomyelitis in rats. *Antimicrob. Agents Chemother.* **58**, 5111–5116 (2014).
15. Lingscheid, T. *et al.* Daptomycin plus fosfomycin, a synergistic combination in experimental implant-associated osteomyelitis due to methicillin-resistant Staphylococcus aureus in rats. *Antimicrob. Agents Chemother.* **59**, 839–843 (2015).
16. Dunne, M. W. *et al.* Extended-duration dosing and distribution of dalbavancin into bone and articular tissue. *Antimicrob. Agents Chemother.* **59**, 1849–1855 (2015).
17. Lopez, S. *et al.* In vitro antistaphylococcal activity of dalbavancin, a novel glycopeptide. *J. Antimicrob. Chemother.* **55**, ii21–24 (2005).
18. Zimmerli, W. Orthopaedic implant-associated infections: Update of antimicrobial therapy. *Orthopade.* **44**, 961–966 (2015).
19. Koeth, L. M., DiFranco-Fisher, J. M. & McCurdy, S. A Reference Broth Microdilution Method for Dalbavancin In Vitro Susceptibility Testing of Bacteria that Grow Aerobically. *J. Vis. Exp.* [https://doi.org/10.3791/53028](https://doi.org/10.3791/53028) (2015).

**Acknowledgements**
This study was presented in part at the European Congress of Clinical Microbiology and Infectious Diseases, Vienna, Austria, 22–25 April 2017 (paper poster session 5708). No external support was obtained for this study. Costs were supported by departmental research funding by the Medical University of Vienna.

**Author Contributions**
M.K., W.P. and H.B. designed the research. M.K., M.O., V.R. and L.V. performed the animal experiments. M.K., M.O., F.B., L.V. and W.P. performed the microbiological assays. M.K. and H.B. analyzed the data. M.K. and W.P. wrote the main manuscript and all authors reviewed and commented on the manuscript.

**Additional Information**

**Competing Interests:** The authors declare no competing interests.

**Publisher’s note:** Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.

---

Open Access This article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons license, and indicate if changes were made. The images or other third party material in this article are included in the article’s Creative Commons license, unless indicated otherwise in a credit line to the material. If material is not included in the article’s Creative Commons license and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this license, visit [http://creativecommons.org/licenses/by/4.0/](http://creativecommons.org/licenses/by/4.0/).

© The Author(s) 2018